查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1316661

癌症支持治疗药物市场：按治疗层级、按用途- 2023-2030 年全球预测

Cancer Supportive Care Drugs Market by Therapeutic Class, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球癌症支持治疗药物市场将大幅成长206.2亿美元，年复合成长率为4.43%，到2030年将达到280.6亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球癌症支持治疗药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.癌症支持治疗药物的全球市场规模和预测是多少？

2.在预测期内，COVID-19对全球癌症支持治疗药物市场的阻碍因素与影响有哪些？

3.在预测期内，全球癌症支持治疗药物市场需要投资哪些产品/细分市场/应用/领域？

4.全球癌症支持治疗药物市场的竞争策略为何？

5. 全球癌症支持治疗药物市场的技术趋势和法律规范是什么？

6.全球癌症支持治疗药物市场主要供应商的市占率是多少？

7. 哪些型态和策略性措施被认为适合进入全球癌症支持治疗药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口增加导致癌症罹患率上升
      • 新产品批准和发布增加
      • 增加癌症支持治疗药物开发的研发活动
    • 抑制因素
      • 癌症支持治疗药物成本高昂
    • 机会
      • 开发新的癌症治疗标靶治疗
      • 生物相似药的采用增加以及政府在医疗保健方面的支出增加
    • 任务
      • 与药物摄取相关的副作用
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章按治疗类别分類的癌症支持治疗药物市场

  • 非类固醇消炎剂
  • 止吐药
  • 双磷酸盐
  • 红血球生成兴奋剂
  • 颗粒细胞增生因子
  • 阿片类药物

第7章癌症支持治疗药物市场：依用途

  • 乳癌
  • 大肠直肠癌
  • 肝癌
  • 肺癌
  • 摄护腺癌
  • 胃癌

第8章美洲癌症支持治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第9章亚太癌症支持治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲癌症支持治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第11章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-450A0628C622

The Global Cancer Supportive Care Drugs Market is forecasted to grow significantly, with a projected USD 20.62 billion in 2023 at a CAGR of 4.43% and expected to reach a staggering USD 28.06 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Supportive Care Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Supportive Care Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Therapeutic Class, market is studied across Non-Steroidal Anti-Inflammatory Drugs, Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents, Granulocyte-Colony Stimulating Factors, and Opioids. The Opioids is projected to witness significant market share during forecast period.

Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer. The Liver Cancer is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Supportive Care Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Supportive Care Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Supportive Care Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Supportive Care Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Supportive Care Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Supportive Care Drugs Market?

6. What is the market share of the leading vendors in the Global Cancer Supportive Care Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Supportive Care Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Supportive Care Drugs Market, by Therapeutic Class, 2022 vs 2030
  • 4.3. Cancer Supportive Care Drugs Market, by Application, 2022 vs 2030
  • 4.4. Cancer Supportive Care Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
      • 5.1.1.2. Increasing approval and launch of new products
      • 5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cancer supportive care drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel targeted therapies for the treatment of cancer
      • 5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with consumption of drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cancer Supportive Care Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs
  • 6.3. Antiemetics
  • 6.4. Bisphosphonates
  • 6.5. Erythropoiesis Stimulating Agents
  • 6.6. Granulocyte-Colony Stimulating Factors
  • 6.7. Opioids

7. Cancer Supportive Care Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Liver Cancer
  • 7.5. Lung Cancer
  • 7.6. Prostate Cancer
  • 7.7. Stomach Cancer

8. Americas Cancer Supportive Care Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cancer Supportive Care Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
  • FIGURE 5. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
  • FIGURE 8. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 105. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 106. CANCER SUPPORTIVE CARE DRUGS MARKET LICENSE & PRICING